Status:
RECRUITING
Effect of a Dietary Supplement on Gut Microbiota and Ocular Surface Outcomes in Dry Eye Disease
Lead Sponsor:
Varol TUNALI
Collaborating Sponsors:
Istanbul Medipol University Hospital
Liv Hospital (Ulus)
Conditions:
Dry Eye
Age-Related Macular Degeneration (AMD)
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This prospective clinical study investigates whether a dietary supplement product can modulate the gut microbiota and improve ocular surface outcomes in patients with dry eye disease. Participants wil...
Detailed Description
Dry eye disease (DED) is a multifactorial ocular surface disorder characterized by chronic tear film instability, hyperosmolarity, and ocular surface inflammation. It represents one of the most common...
Eligibility Criteria
Inclusion
- Clinical diagnosis of dry eye disease.
- Age 18-65 years.
- Willing and able to provide informed consent.
Exclusion
- Current restrictive diet (ketogenic, elimination, prolonged fasting, etc.).
- Colonoscopy or systemic antibiotic use within the past 4 weeks.
- Use of probiotic, prebiotic, or fecal microbiota-related products within the past 4 weeks.
- Other systemic or ocular conditions that could interfere with study outcomes.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07148271
Start Date
October 1 2025
End Date
January 30 2026
Last Update
November 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medipol University
Istanbul, Turkey (Türkiye)